Advertisement
Advertisement

ANIK

ANIK logo

Anika Therapeutics Inc

9.21
USD
Sponsored
+0.06
+0.71%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

9.23

+0.02
+0.21%

ANIK Earnings Reports

Positive Surprise Ratio

ANIK beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report
Mar 10, 2026
Estimate for Q4 25 (Revenue/ EPS)
$29.45M
/
-$0.21
Implied change from Q3 25 (Revenue/ EPS)
+5.88%
/
+31.25%
Implied change from Q4 24 (Revenue/ EPS)
-3.76%
/
-86.00%

Anika Therapeutics Inc earnings per share and revenue

On Nov 05, 2025, ANIK reported earnings of -0.16 USD per share (EPS) for Q3 25, beating the estimate of -0.27 USD, resulting in a 41.90% surprise. Revenue reached 27.82 million, compared to an expected 28.36 million, with a -1.90% difference. The market reacted with a +2.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.21 USD, with revenue projected to reach 29.45 million USD, implying an increase of 31.25% EPS, and increase of 5.88% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Anika Therapeutics Inc reported EPS of -$0.16, beating estimates by 41.9%, and revenue of $27.82M, -1.9% below expectations.
The stock price moved up 2.28%, changed from $9.63 before the earnings release to $9.85 the day after.
The next earning report is scheduled for Mar 10, 2026.
Based on 4 analysts, Anika Therapeutics Inc is expected to report EPS of -$0.21 and revenue of $29.45M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement